These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 10592500)

  • 1. Apoptosis, mitosis, p53, bcl(2), Ki-67 and clinical outcome in prostate carcinoma treated by androgen ablation.
    Szende B; Romics I; Torda I; Bély M; Szegedi Z; Lovász S
    Urol Int; 1999; 63(2):115-9. PubMed ID: 10592500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repeated biopsies in evaluation of therapeutic effects in prostate carcinoma.
    Szende B; Romics I; Minik K; Szabó J; Torda I; Lovász S; Szomor L; Tóth L; Bély M; Kerényi T; Bartók K; Végh A
    Prostate; 2001 Oct; 49(2):93-100. PubMed ID: 11582587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The role of repeated biopsies in prognosis of prostate cancer].
    Romics I; Lovász S; Szabó J; Szomor L; Minik K; Bartók K; Kerényi T; Szende B
    Orv Hetil; 2002 Jul; 143(27):1619-23. PubMed ID: 12179998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Follow-up of prostate carcinoma patients treated with total androgen blockade by repeated map-biopsy.
    Szabo J; Bartok K; Keréni T; Vegh A; Romics I; Szende B
    Ann Urol (Paris); 2000 Aug; 34(4):236-9. PubMed ID: 10994142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression.
    Baretton GB; Klenk U; Diebold J; Schmeller N; Löhrs U
    Br J Cancer; 1999 May; 80(3-4):546-55. PubMed ID: 10408865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H; Hara I; Eto H
    BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor expression in relation to apoptosis and the expression of cell cycle related proteins in prostate cancer.
    Amirghofran Z; Monabati A; Gholijani N
    Pathol Oncol Res; 2004; 10(1):37-41. PubMed ID: 15029260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation.
    Matsushima H; Goto T; Hosaka Y; Kitamura T; Kawabe K
    Cancer; 1999 Apr; 85(8):1822-7. PubMed ID: 10223578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of Ki-67 expression in advanced prostate cancers in relation to disease progression after androgen ablation.
    Matsuura H; Hayashi N; Kawamura J; Shiraishi T; Yatani R
    Eur Urol; 2000 Feb; 37(2):212-7. PubMed ID: 10705201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610.
    Grignon DJ; Caplan R; Sarkar FH; Lawton CA; Hammond EH; Pilepich MV; Forman JD; Mesic J; Fu KK; Abrams RA; Pajak TF; Shipley WU; Cox JD
    J Natl Cancer Inst; 1997 Jan; 89(2):158-65. PubMed ID: 8998185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors.
    Nariculam J; Freeman A; Bott S; Munson P; Cable N; Brookman-Amissah N; Williamson M; Kirby RS; Masters J; Feneley M
    Asian J Androl; 2009 Jan; 11(1):109-18. PubMed ID: 19050681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors in prostate cancer.
    Stattin P
    Scand J Urol Nephrol Suppl; 1997; 185():1-46. PubMed ID: 9249905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of Bcl-2, Bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation.
    Johnson MI; Robinson MC; Marsh C; Robson CN; Neal DE; Hamdy FC
    Prostate; 1998 Dec; 37(4):223-9. PubMed ID: 9831218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.
    Gleave ME; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD
    J Urol; 1996 Jan; 155(1):213-9. PubMed ID: 7490838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined androgen blockade in the management of advanced prostate cancer: a sensible or ostensible approach.
    Ansari MS; Gupta NP; Hemal AK; Dogra PN; Seth A
    Int J Urol; 2004 Dec; 11(12):1092-6. PubMed ID: 15663681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
    Boccon-Gibod L; Fournier G; Bottet P; Marechal JM; Guiter J; Rischman P; Hubert J; Soret JY; Mangin P; Mallo C; Fraysse CE
    Eur Urol; 1997; 32(4):391-5; discussion 395-6. PubMed ID: 9412794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
    Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
    Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of pretreatment expression of androgen receptor and bcl-2 in hormonally treated prostate cancer patients.
    Noordzij MA; Bogdanowicz JF; van Krimpen C; van der Kwast TH; van Steenbrugge GJ
    J Urol; 1997 Nov; 158(5):1880-4; discussion 1884-5. PubMed ID: 9334622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.